Sanofi Contingent Value Rights

Sanofi Contingent Value Rights Aktie WKN: A1H859 ISIN: US80105N1138 buran

Datum Erster Hoch Tief Schluss     Stücke Volumen
01.11.13 1,92 1,95 1,89  1,90 $ 403.870 0,77 M

GrB

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi, CVR - GCVRZ

22:10 08.11.13

PR Newswire

NEW YORK, Nov. 8, 2013

NEW YORK, Nov. 8, 2013 /PRNewswire/ -- Pomerantz Grossman Hufford Dahlstrom & Gross LLP is investigating claims on behalf of investors of Sanofi, CVR ("Sanofi" or the "Company")(NASDAQ: GCVRZ).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.

The investigation concerns whether Sanofi and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.  On November 8, 2013, shares of Sanofi fell in massive volume after a report was released by Reuters which stated that U.S. regulatory officials have raised concerns about "multiple serious and potentially fatal safety issues" in patients given Sanofi's new multiple sclerosis drug Lemtrada, fuelling uncertainty about whether it will be approved.

On this news, shares of Sanofi fell $1.18 per share to more than 59.00% on intraday trading to a price of $0.82 on November 8, 2013.

The Pomerantz Firm, with offices in New York, Chicago, San Diego and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:

Robert S. Willoughby

Pomerantz Grossman Hufford Dahlstrom & Gross LLP

rswilloughby@pomlaw.com

SOURCE Pomerantz Grossman Hufford Dahlstrom & Gross LLP
Quelle: PR Newswire

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Sanofi

14:35 11.11.13

PR Newswire

NEW YORK, Nov. 11, 2013

NEW YORK, Nov. 11, 2013 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Sanofi. ("Sanofi" or the "Company") (NasdaqGM: GCVRZ -News).  Such investors are advised to contact Peretz Bronstein or his investor Relation's coordinator Eitan Kimelman at info@bgandg.com or 212-697-6484.

The investigation concerns whether Sanofi and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.  On November 8, 2013 shares of Sanofi fell 1.23 or 61.5% to close at $0.77, after an FDA briefing report has revealed strong safety concerns with the company's multiple sclerosis treatment, Lemtrada, fueling uncertainty about whether it will be approved.

If you are aware of any facts relating to this investigation, or purchased shares of Sanofi, you can assist this investigation by contacting Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com.  Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Eitan Kimelman 212-697-6484

info@bgandg.com

SOURCE Bronstein, Gewirtz & Grossman, LLC
Quelle: PR Newswire

Lawsuit Against Sanofi
00:10 13.12.13

PR Newswire

WAYNE, Pa., Dec. 12, 2013

WAYNE, Pa., Dec. 12, 2013 /PRNewswire/ -- Ryan & Maniskas, LLP announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York on behalf of purchasers of Sanofi contingent value rights (NASDAQ: GCVRZ) ("CVRs" or "shares") between March 6, 2012 and November 7, 2013, inclusive (the "Class Period").

(Logo: photos.prnewswire.com/prnh/20121112/MM11729LOGO )

For more information regarding this class action suit, please contact Ryan & Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at (877) 316-3218 or by email at rmaniskas@rmclasslaw.com or visit: www.rmclasslaw.com/cases/gcvrz.  

Sanofi is a global pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products. Many of the Company's products are regulated by the United States Food and Drug Administration ("FDA"), which oversees the Company's compliance with applicable rules and regulates the Company's covered products such as vaccines and pharmaceuticals.

On or around February 16, 2011, Sanofi signed an agreement (the, "Merger Agreement") to acquire Genzyme Corporation ("Genzyme") and substantially all of Genzyme's assets.  One of the most important drugs in development by Genzyme at the time of the acquisition was Lemtrada, a treatment for multiple sclerosis ("MS").  Sanofi (and Genzyme as its subsidiary) strongly touted the efficacy and safety of Lemtrada, by directing investors' attention to two pivotal studies which the Company claimed demonstrated the safety and efficacy of Lemtrada.  In connection with the Genzyme acquisition, Sanofi agreed to amend the outstanding tender offer to acquire all of the outstanding shares of common stock of Genzyme (the "Genzyme Shares") in order to increase the price per share from $69.00 to $74.00 in cash plus one CVR to be issued by Sanofi, subject to and in accordance with a CVR Agreement, per Genzyme Share.

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, the complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose the following:  (a) that Defendants had materially misrepresented the safety and efficacy of Lemtrada in statements to investors and the public; (b) that the design of the Lemtrada 323 and 324 trials had been materially misrepresented to investors and the public, with Defendants failing to disclose that the trials contained high levels of placebo effect and observer bias, which tainted the results and thereby lowered the likelihood of Lemtrada approval by the FDA; (c) that the Company lacked adequate internal controls; and (d) that as a result of the foregoing, Defendants lacked a reasonable basis for their positive statements about Lemtrada and its prospects.

On November 8, 2013, the FDA Advisory Committee on Peripheral and Central Nervous System Drugs issued a briefing report (the "Briefing Report") in advance of its November 13, 2013 hearing.  The Briefing Report sharply criticized the Company's submission to the FDA, and found that "significant concerns exist regarding the safety profile of alemtuzumab [Lemtrada] and the adequacy of the efficacy data."  On this news, Sanofi's CVRs declined $1.23 per share, or nearly 62%, to close at $0.77 per share on November 8, 2013 on volume of over 30 million shares.

If you are a member of the class, you may, no later than February 10, 2014, request that the Court appoint you as lead plaintiff of the class.  A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation.  In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class.  Under certain circumstances, one or more class members may together serve as "lead plaintiff."  Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff.  You may retain Ryan & Maniskas, LLP or other counsel of your choice, to serve as your counsel in this action.

For more information about the case or to participate online, please visit: www.rmclasslaw.com/cases/gcvrz or contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218, or by e-mail at rmaniskas@rmclasslaw.com.  For more information about class action cases in general or to learn more about Ryan & Maniskas, LLP, please visit our website: www.rmclasslaw.com.

Ryan & Maniskas, LLP is a national shareholder litigation firm.  Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.

CONTACT:              

Ryan & Maniskas, LLP

Richard A. Maniskas, Esquire

995 Old Eagle School Rd., Suite 311

Wayne, PA 19087

484-588-5516

877-316-3218

www.rmclasslaw.com/cases/gcvrz  

rmaniskas@rmclasslaw.com

SOURCE Ryan & Maniskas, LLP


Quelle: PR Newswire

     1.500          §
  15:45:39§0,3698 $
     1.600          §
  15:45:39§0,3699 $
     6.900          §
  15:42:51§0,3698 $
     6.655          §
  15:41:47§0,365 $
     2.500          §
  15:39:23§0,37 $
     2.800          §
  15:39:08§0,37 $
     1.000          §
  15:39:07§0,37 $
     1.000          §
  15:39:06§0,37 $
     1.000          §
  15:39:06§0,367 $
       700          §
  15:39:06§0,37 $
       300          §
  15:39:05§0,37 $
     3.000          §
  15:38:57§0,37 $
     4.900          §
  15:37:51§0,37 $
    10.000          §
  15:36:09§0,37 $
    10.000          §
  15:35:06§0,37 $
     2.000          §
  15:34:55§0,37 $
     4.900          §
  15:34:54§0,37 $
     5.000          §
  15:34:51§0,37 $
    23.000          §
  15:34:50§0,37 $
     4.000          §
  15:34:49§0,37 $
     1.000          §
  15:34:48§0,37 $
     1.000          §
  15:34:47§0,37 $
     1.000          §
  15:34:46§0,37 $
       100          §
  15:34:45§0,37 $
     1.900          §
  15:34:44§0,37 $
     2.000          §
  15:34:14§0,37 $
    10.000          §
  15:34:01§0,37 $
     6.000          §
  15:33:58§0,3701 $
     4.000          §
  15:33:03§0,37 $
     7.700          §
  15:32:46§0,3701 $
     2.300          §
  15:30:56§0,37 $
     6.046          §
  15:30:55§0,3699 $
     1.000          §
  15:30:40§0,37 $
    12.694          §
  15:30:28§0,37 $
       400          §
  15:30:27§0,37 $
     1.600          §
  15:30:00§0,37 $
10.983

GrB

Preis pro share 0,3698 $ Schleife 1.600 spread 1,32%

buran und MfG und danke und weiter weiter immer schneller wie Propeller

RTK 0,3595  $ RTP -2,04 EK 0,367 $ last shares 1.200 full realtime 3.580.915 peak 0,3701

buran und MfG und danke und weitermachen und trullala

::::::::::::::: 0,37 $ +1,09% +0,004 $
In Euro: 0,2710 € | Nasdaq, 10.01.14:::::::: wagen nicht nur klagen Leben so wie ich es mag Tag für Tag ohne Muff und Enge immer auf dem Börsenplatze in der Tickerleuchten Menge ..::hopshopshopshopshopshopshopshopshopshops

buran & Sanofi,Die Börsen Ticker Platz Engen Muffis

Börsenbucheinsicht

http://www.ariva.de/...alue_rights-aktie/times_and_sales?boerse_id=40 GrB

Class Action Against Sanofi Pharmaceuticals, Inc. and Certain Officers - GCVRZ
23:40 24.01.14

PR Newswire

NEW YORK, Jan. 24, 2014

NEW YORK, Jan. 24, 2014 /PRNewswire/ -- Pomerantz LLP has filed a class action lawsuit against Sanofi Pharmaceuticals, Inc. ("Sanofi" or the "Company") (Nasdaq: GCVRZ) and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and docketed under 13-cv-8991, is on behalf of a class consisting of all persons or entities who purchased or otherwise acquired Contingent Value Rights-2011 ("CVR's") related to the performance of the Company's anti Multiple Sclerosis ("MS") drug Lemtrada. (CUSIP: 80105N113) between March 6, 2012 and November 7, 2013 both dates inclusive (the "Class Period"). This class action seeks to recover damages against the Company and certain of its officers and directors as a result of alleged violations of the federal securities laws pursuant to Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

If you are a shareholder who purchased the CVR's during the Class Period, you have until February 10, 2014 to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888.476.6529 (or 888.4-POMLAW), toll free, x237. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.

Sanofi is a global pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products. Sanofi is the fifth largest pharmaceutical group in the world and the third largest pharmaceutical group in Europe. The company operates three main product segments: Pharmaceuticals, Human Vaccines, and Animal Health.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business and operations. Specifically, during the Class Period, Defendants misrepresented to investors the efficacy and safety of the Company's MS drug Lemtrada. The Company also misled investors regarding the design of its two Lemtrada pivotal trials, the 323 and 324 trials, specifically failing to disclose that the trials contained high levels of placebo effect and observer bias which tainted the results, and thereby lowered the likelihood of approval of Lemtrada by the FDA.

On November 8, 2013, the FDA Advisory Committee on Peripheral and Central Nervous System Drugs issued a briefing report (the, "Briefing Report") in advance of its November 13, 2013 hearing. The Briefing Report sharply criticized the Company's submission to the FDA, and found that, "significant concerns exist regarding the safety profile of alemtuzumab [Lemtrada] and the adequacy of the efficacy data." On this news, Sanofi's CVRs declined $1.23 per share or nearly 62%, to close at $0.77 per share on November 8, 2013 on volume of over 30 million shares.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and San Diego, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:

Robert S. Willoughby

Pomerantz LLP

rswilloughby@pomlaw.com

SOURCE Pomerantz LLP


Quelle: PR Newswire

  12.02.14      0,37     0,414§0,3611 0,3979 $ 1.007.422 368 T
  11.02.14    0,3828      0,39§0,37 0,372 $ 753.841 284 T
  10.02.14    0,3808      0,40§0,3808 0,386 $ 532.908 204 T
  07.02.14    0,4003      0,42§0,3885 0,39 $ 771.517 305 T
  06.02.14    0,4208    0,4255§0,39 0,4003 $ 6.172.761 2,05 M
  05.02.14    0,4318      0,46§0,4209 0,424 $ 1.181.582 0,51 M
  04.02.14      0,45      0,46§0,4309 0,45 $ 351.559 155 T

GrB

http://www.ariva.de/...alue_rights-aktie/times_and_sales?boerse_id=40 GrB

Datum Erster Hoch Tief Schluss     Stücke Volumen
  03.06.14      0,52      0,53§0,50 0,50 $ 1.471.111 0,75 M

GrB

Buch dazu
http://www.ariva.de/...alue_rights-aktie/times_and_sales?boerse_id=40 GrB

Preis pro share 0,4998 $ Schleife 2.400 spread 4,10% buran und MfG und lass krachennnnn ..:hopshops

buran: nur ein börsenboard geführt von www.bundesbank.de 21:18 #1
achte er einfach auf die links
Mit freundlichen Grüssen Mario Meierhof 39517 Lüderitz Gartenstrasse 6
mariomeierhof@web.de
Tel.:039361/96548 Atelier Meierhof 039361/51273 Kuhle
gez MARIO alias buran http://www.ariva.de/…/nur-ein-boersenboard-gefuehrt-von-www…

Deutsche Bundesbank - Startseite
Die Deutsche Bundesbank ist die Zentralbank der Bundesrepublik Deutschland. Zentrales Geschäftsfeld ist die Geldpolitik des Eurosystems.
BUNDESBANK.DE
https://www.facebook.com/mario.meierhof

Der Schlußkurs wird nach dem akustischen Zeichen festgestellt, das die Beendigung des Präsenzhandels ankündigt. Ein Anspruch auf Berücksichtigung bei der Preisermittlung haben nur solche Aufträge, die bis zu diesem Zeitpunkt beim Kursmakler vorliegen und die zum fortlaufenden Handel (Variable Notierung) geeignet sind. http://www.ariva.de/extras/lexikon.m?begriff=Schlusskurs

..yöah

-63,04%

..yöah

GRINS ...

Buch
http://www.ariva.de/...alue_rights-aktie/times_and_sales?boerse_id=40 GrB

Preis pro share 0,1251 $ Schleife 100 spread 0,08% buran und MfG und allet watt schleift ..heift heift

Buch http://www.ariva.de/...alue_rights-aktie/times_and_sales?boerse_id=40 GrB

http://www.ariva.de/sanofi_contingent_value_rights-aktie/kurs GrB

:::::::::::::: 0,48 $ +0,27% +0,0013 $
In Euro: 0,4489 € | 27.01.17 Nasdaq ,GrB

Results were reviewed by management at a conference call with the financial community. en.sanofi.com/investors/